JNJ-26854165 (Serdemetan)

Name: JNJ-26854165 (Serdemetan)
Brand: Selleck Chemicals
SKU: S1172
Rating: 5 (7 reviews)

For research use only. Not for use in humans.

Catalog No.S1172

7 publications

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Selleck's JNJ-26854165 (Serdemetan) has been cited by 7 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra98

PubMed: 27703031 ( click the link to review the publication )

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

Sci Rep, 2014, 4:4664

PubMed: 24722541 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	M3[0OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV23SpRVUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOUOyN\|Yh\|ryP	NF;DR5RUSU6JRWK=
H4 cell	MnfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGfXOWZKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wOlcxPyEQvF2=	MW\TRW5ITVJ?
KGN cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVvJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwNkKwOUDPxE1?	NWTpbmJyW0GQR1XS
786-0 cell	M1rMPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63Nlk5QSEQvF2=	M2jKS3NCVkeHUh?=
769-P cell	NF35cHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mn3mTY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFIzOjRizszN	MYfTRW5ITVJ?
K5 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYLqNYtCUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFE3OjRizszN	M4LlOXNCVkeHUh?=
MLMA cell	M2\1OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGmy[WZKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODN{MUeg{txO	MUnTRW5ITVJ?
MLMA cell	M3vjWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkK4O\|A{KM7:TR?=	M4XWXHNCVkeHUh?=
EW-7 cell	NHPGU\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYXJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?=	MXnTRW5ITVJ?
SW1088 cell	NYT0d4t5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NG\tfVFKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDB4NUGg{txO	NVj4VXhIW0GQR1XS
MC-IXC cell	Mkj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEPIVWdKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO	NHOxNGxUSU6JRWK=
NCI-H2052 cell	M2nBNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3ftVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1?	M2PZXXNCVkeHUh?=
IGR-1 cell	NILRdFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYrYfnk2UW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO	MmTVV2FPT0WU
DSH1 cell	NWjSU2JRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Ml7XTY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6yOFI6PiEQvF2=	MojBV2FPT0WU
PA-1 cell	NXrXZnJYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkOwNFU6\|ryP	NXPFNoJVW0GQR1XS
SK-MEL-3 cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHi4V4xKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5\|MUKwO{DPxE1?	NFnCXmJUSU6JRWK=
SW900 cell	NXnsd4dwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXfJN3NJUW6qaXLpeIlwdiCxZjDoeY1idiCVV{mwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDh{NUWg{txO	MUTTRW5ITVJ?
CAKI-1 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{K1SmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{42Ojd\|ODFOwG0>	MYjTRW5ITVJ?
ES1 cell	M2nPSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUXubnlVUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzQDl5IN88US=>	NYTJOJl1W0GQR1XS
SK-N-DZ cell	MmT3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NV\iOGNPUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54MkW5OUDPxE1?	M2W1RnNCVkeHUh?=
RH-1 cell	NWjORWJvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGTFZZVKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ\|IN88US=>	Mlf0V2FPT0WU
ES8 cell	NGHQcm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUHmc4l4UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY6PzB{IN88US=>	NXHxZVg3W0GQR1XS
NEC8 cell	MlzTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mo\rTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz63Olk5OiEQvF2=	NIeyS4dUSU6JRWK=
LNCaP-Clone-FGC cell	NHPFOnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MknkTY5pcWKrdHnvckBw\iCqdX3hckBNVkOjUD3DcI9v\S2IR1OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg{PTN4IN88US=>	M1LJWnNCVkeHUh?=
HCE-4 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkXETY5pcWKrdHnvckBw\iCqdX3hckBJS0VvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPVgxPyEQvF2=	M2npT3NCVkeHUh?=
U-118-MG cell	M3vQUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NI\C[GxKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1?	MYXTRW5ITVJ?
GI-ME-N cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mlq5TY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDd7NjFOwG0>	MW\TRW5ITVJ?
LB1047-RCC cell	NGGzc\|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHuwNXhKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG2NVQ{KM7:TR?=	MlLNV2FPT0WU
HT-1080 cell	MoPzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NE\Jfo9KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>?	MWnTRW5ITVJ?
NB69 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2DtU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|UxPDdizszN	NEfZVGZUSU6JRWK=
NCI-H1693 cell	NXqyZYxIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2jQcWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52NEi5OUDPxE1?	MWnTRW5ITVJ?
HSC-3 cell	NVzFSHFTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MojFTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFk6OzNizszN	NGjzdmhUSU6JRWK=
MDA-MB-231 cell	M1vyUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>?	M2r2WHNCVkeHUh?=
HOS cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwN{i2N{DPxE1?	NEHK[nVUSU6JRWK=
BT-549 cell	Mmn5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH;pdIxKdmirYnn0bY9vKG:oIHj1cYFvKEKWLUW0PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzh6NzFOwG0>	NXq4bVkxW0GQR1XS
NB17 cell	MnrvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1nNTmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|g6PzZizszN	MmXvV2FPT0WU
5637 cell	MnXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUjJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke5OlUzKM7:TR?=	MkLuV2FPT0WU
OVCAR-8 cell	M4LtUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlvRTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR\|NjFOwG0>	MVLTRW5ITVJ?
G-402 cell	NULyPW1oT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NI\jZXdKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OzB\|NTFOwG0>	MkHJV2FPT0WU
BB30-HNC cell	MkXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mme5TY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO	M1zEcXNCVkeHUh?=
HCC1806 cell	Mn7jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnPVTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOEC2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xQDN\|OTFOwG0>	M3T3V3NCVkeHUh?=
COLO-800 cell	NGjCc3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHrCUG1KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5zMk[0JO69VQ>?	M4K0OHNCVkeHUh?=
FADU cell	NEO0WFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mmm4TY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6zOlU2PyEQvF2=	NXX6b\|RGW0GQR1XS
NCI-H1651 cell	MorsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEDmOXdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwM{m0NFkh\|ryP	MnyzV2FPT0WU
AGS cell	NFnidmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnnhTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O\|EyKM7:TR?=	MnPGV2FPT0WU
CHP-212 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=>	MYnTRW5ITVJ?
YAPC cell	M3GzVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NITuVXpKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=>	M3PRVHNCVkeHUh?=
GOTO cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV7yRpNPUW6qaXLpeIlwdiCxZjDoeY1idiCJT2TPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41QTV5NjFOwG0>	M{Xl[HNCVkeHUh?=
KYSE-510 cell	MnjvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF7Ce5dKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53MUGg{txO	M3vD[HNCVkeHUh?=
NCI-H2342 cell	M1nlfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYPJdpR3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNlc5KM7:TR?=	Ml7IV2FPT0WU
BFTC-905 cell	MortS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWfJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh\|NTFOwG0>	MnfoV2FPT0WU
EW-16 cell	NVXZSpM6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX7COXdRUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyOUOg{txO	Ml2yV2FPT0WU
SK-MEL-30 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnTSTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njd2NUSzJO69VQ>?	M2LWOHNCVkeHUh?=
HLE cell	NX62SY1HT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnLtTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3OFg6KM7:TR?=	M4O3cXNCVkeHUh?=
T98G cell	M1LLNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3zBcmlvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|k3OzVizszN	NGrZZphUSU6JRWK=
HUTU-80 cell	NH:2OJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXHPT\|RrUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NEKyPEDPxE1?	NIP5OnJUSU6JRWK=
NOS-1 cell	NF;Jb\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3nsUGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk1PzZ4IN88US=>	NVy0XG95W0GQR1XS
SW780 cell	M{XTVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXPKcGZtUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO	MnGzV2FPT0WU
KYSE-180 cell	NHrYUIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkXqTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd4NUSg{txO	Mk\IV2FPT0WU
MDA-MB-361 cell	NHvu[JZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl6NkS3JO69VQ>?	NEXZXHlUSU6JRWK=
SNU-C2B cell	M4nObWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mnf4TY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF\|ODFOwG0>	NUi5UFFkW0GQR1XS
NCI-H661 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIDrWmZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlYyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5yNkm0JO69VQ>?	M4TIS3NCVkeHUh?=
OE33 cell	MkPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWrJcohq[mm2aX;uJI9nKGi3bXHuJG9GOzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkG0N\|g6KM7:TR?=	NWDCR49RW0GQR1XS
TYK-nu cell	M2SzcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXjJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNlE5PjNizszN	M{mzenNCVkeHUh?=
COLO-792 cell	NHfDZ4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmTITY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjV{MUmg{txO	MYTTRW5ITVJ?
HEL cell	NF\TfZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGXONo1KdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNlY4PiEQvF2=	NIOyN2lUSU6JRWK=
D-566MG cell	NF;3eGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHS1THZKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN\|NEmxJO69VQ>?	M4PEd3NCVkeHUh?=
U031 cell	Ml3oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NETufFFKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=>	NGW5W\|FUSU6JRWK=
COR-L23 cell	NHHjdo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVnJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{OzR4IN88US=>	NGjqUndUSU6JRWK=
NCI-H2452 cell	MlW1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX\lOWRUUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1PTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkWyNlgyKM7:TR?=	MWHTRW5ITVJ?
BB65-RCC cell	MmXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{GzOWlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO	MmjFV2FPT0WU
CAL-33 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOlU3PjVizszN	MWnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p53 / HDM2 / HDMX / p21 / Noxa / Puma ; PubMed: 20736344 Mol Cancer Ther OCI-AML-3 and MOLM-13 cells were incubated with a range of concentrations of JNJ-26854165 for 18 hours. ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; PubMed: 23820125 J Pharmacol Exp Ther U266 and JeKo-1 cells were treated with JNJ-26854165 and cells harvested at the indicated time points. MDM2 / p-MDM2 / p53 ; PubMed: 27999193 Oncotarget K562 cells was harvested at 48 h after treatment with various JNJ-165 concentrations, and then nuclear and cytoplasmic extracts were prepared to check the levels of p53, MDM2 and p-MDM2 by Western blotting. Actin and LaminB were used as loading control respectively. Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 ; PubMed: 27999193 Oncotarget CML cell lines were treated with JNJ-165 at the indicated doses for 48 h. Whole-cell lysates were extracted to assess the levels of BCR-ABL and phosphorylated (p)-BCR-ABL (Tyr177), and then were analyzed for BCR-ABL downstream signaling mediators p-CrkL (Try207), total Stat5, p-Stat5 (Tyr694), total Stat3, and p-Stat3 (Ser727) expression by Western blot analysis. The expression of β-actin was used as loading control. The data are representative of three determinations with identical results.	20736344 23820125 27999193
Growth inhibition assay	Cell viability; PubMed: 23820125 J Pharmacol Exp Ther MCL (B) and MM (C) cell lines were seeded in 96-well plates for viability analyses using WST-1 and treated with JNJ-26854165 for 72 hours. Results are expressed as the percentage of cell viability in relation to the vehicle-treated sample for each cell line, which was arbitrarily set at 100%	23820125
Immunofluorescence	p53; PubMed: 27999193 Oncotarget Two-color fluorescence microscope analysis of antibody against p53 protein (green) and nuclei (DAPI staining, blue) showed nuclear accumulation of p53 in K562 cells with treatment of 1 μM JNJ-165, but not in control-treated cells after 48 h. Images were taken on a fluorescence microscopy (100×).	27999193

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: CB17SC scid^-/- female mice.
Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Ethanol	2 mg/mL (6.08 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	C(CC1=C[NH]C2=CC=CC=C12)NC3=CC=C(NC4=CC=NC=C4)C=C3

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity.
NSC 319726

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

Features:An allele-specific p53 mutant reactivator.
Pifithrin-μ

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)